Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Protara Therapeutics (TARA) Shares Outstanding (2016 - 2026)

Protara Therapeutics' Shares Outstanding history spans 14 years, with the latest figure at $55.1 million for Q1 2026.

  • Quarterly Shares Outstanding rose 42.71% to $55.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.1 million through Mar 2026, up 42.71% year-over-year, with the annual reading at $53.6 million for FY2025, 670495.17% up from the prior year.
  • Shares Outstanding came in at $55.1 million for Q1 2026, up from $53.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $55.1 million in Q1 2026 to a low of $5615.0 in Q1 2025.
  • The 5-year median for Shares Outstanding is $11.3 million (2022), against an average of $15.9 million.
  • Year-over-year, Shares Outstanding tumbled 99.93% in 2024 and then surged 670495.17% in 2025.
  • Protara Therapeutics' Shares Outstanding stood at $8027.0 in 2022, then dropped by 0.45% to $7991.0 in 2023, then changed by 0.0% to $7991.0 in 2024, then soared by 670495.17% to $53.6 million in 2025, then grew by 2.74% to $55.1 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Shares Outstanding are $55.1 million (Q1 2026), $53.6 million (Q4 2025), and $38.6 million (Q3 2025).